Morrill J C, Czarniecki C W, Peters C J
Disease Assessment Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011.
J Interferon Res. 1991 Oct;11(5):297-304. doi: 10.1089/jir.1991.11.297.
Prophylactic treatment of rhesus macaques with 10(4)-10(6) U/kg of recombinant human interferon-gamma (rHuIFN-gamma) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-gamma and rHuIFN-alpha A.
用10⁴-10⁶U/kg重组人干扰素-γ（rHuIFN-γ）对恒河猴进行预防性治疗可调节裂谷热（RVF）病毒感染。在感染前24小时肌肉注射干扰素，此后每天注射一次，共注射五剂。感染后，接受治疗的猴子没有出现临床疾病迹象；一些猴子没有可检测到的病毒血症；当观察到病毒血症时，与感染对照猴子相比，病毒峰值滴度降低；并且在血液学和临床化学值方面仅出现轻微和短暂的波动。未治疗的感染对照猴子出现高滴度病毒血症、轻度至重度临床疾病以及止血参数和临床实验室测量值的中度至重度变化。当用低剂量rHuIFN-γ和rHuIFN-αA联合对感染RVF病毒的猴子进行预防性治疗时，未观察到协同作用的迹象。
